Tag Archives: IPO

What’s Behind the Biotech IPO Boom?

BIOtech-stocks

Everyone knows that it’s been a knock-out year for the biotech sector in the public markets, which includes a large and well-performing IPO class. So far in 2013, 39 US-based companies have gone public, five European-based companies, and one Canadian company. Of these 45 IPOs, 42 companies have gone public on US stock exchanges. That’s over double the amount we saw in 2012. This year’s IPOs have also been successful at raising the amount of money Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Lots of Buzz at the BIO Investor Forum

Event

Thirty-eight biotech IPO’s this year. The NASDAQ Biotechnology Index is up 50 percent YTD.  Are we in a boom or a bubble? At the 12th Annual BIO Investor Forum,  that was the question on everybody’s mind. Nearly 600 biotech industry leaders, investors, and reporters gathered in San Francisco to find business partners, make connections, and hear our panelists discuss everything from Crowdfunding, the GAIN Act, the JOBS Act, and, of course, the booming IPO markets. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The New Road to IPO in the Age of the JOBS Act

President Obama

Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend to fill the room. Furthermore, it should surprise no one that this year’s IPO discussions were upbeat. That is mostly attributable to the dramatically higher number of IPOs that have already occurred this year. Furthermore, according to Jeff Baumel, moderator of a panel covering this very topic, deals are closing faster this year – with a median time of just Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

David Thomas

With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market. Is it a bubble? David Thomas, director of Industry Research and Analysis at BIO took up these questions during the opening plenary lunch of the 12th Annual BIO Investor Forum. What’s his short answer? Not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,